Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center

The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México. This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identif...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista de investigacion clinica 2020-10, Vol.73 (5), p.94-99
Hauptverfasser: Córdova-Ramírez, Alejandra C, Sánchez-Valledor, Luisa F, Colón-Otero, Gerardo, Rivera-Alvarez, Montserrat, Elías-de-la-Cruz, Gilberto D, Murrieta-Alvarez, Iván, Cantero-Fortiz, Yahveth, León-Peña, Andrés, Olivares-Gazca, Juan C, Ruiz-Delgado, Guillermo J, Ruiz-Argüelles, Guillermo J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México. This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified. There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006). Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.
ISSN:0034-8376
2564-8896
DOI:10.24875/RIC.20000381